Skip to search formSkip to main contentSkip to account menu
Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies
TLDR
Pharmacokinetics and radiation dosimetry for a commercial preparation of samarium-153 ethylene diamine tetramethylene phosphonate (EDTMP; Quadramet) were evaluated in 43 tracer studies of 42 patients with haematological malignancies and myelosuppression was achieved without evidence of myelofibrosis.
View on Springer
Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib
TLDR
Early (d14) FDG-PET PMR is associated with improved PFS and OS, even in the absence of subsequent Response Evaluation Criteria in Solid Tumors response, and these data support inclusion of FDg-PET imaging in clinical trials testing novel targeted therapies, particularly those with anticipated cytostatic effects.
View on Publisher
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
TLDR
This update of the Phase I results after 1311 anti-B1 antibody treatment for NHL indicates that CRs can be durable and that survival can be of long duration.
View on PubMed
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
TLDR
CMD-193 shows rapid blood clearance and increased hepatic uptake compared with prior studies of the parental antibody hu3S193, highlighting the importance of biodistribution and pharmacodynamic assessment in early phase studies of new biologics to assist in clinical development.
View on Publisher
Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
TLDR
FDG SPECT performed with a specially collimated triple-head gamma camera depicted some cancers but had an unacceptably low sensitivity compared with PET for lesions less than 3 cm in diameter, suggesting PET is preferable for detecting small cancers.
View on PubMed
Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
TLDR
FDG-PET accurately predicted regional node status in 88% of CMM cases, but the failure to detect micrometastatic disease may be due to the limitations of the imaging equipment and technique used here.
View on PubMed
Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03
TROG 09.03 prospectively studied the utility of Fluorine‐18 Fluorodeoxyglucose (18‐FDG) PET in the management of Merkel cell carcinoma of skin.
View on Wolters Kluwer
Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′
TLDR
99mTc-DI-80B3 Fab’ is well tolerated, is rapidly cleared and exhibits clinically acceptable dosimetry—characteristics well suited to a potential thrombus imaging agent.
View on Springer
153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies
This study examined the safety of adding 153Sm lexidronam to standard conditioning regimens in patients undergoing stem cell transplantation for marrow based haematological malignancies in whom…
View on Wolters Kluwer
FDG PET imaging of paragangliomas of the neck: comparison with MIBG SPET
Two patients with cervical paragangliomas underwent positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). There was marked tumor uptake and retention of FDG. Adjacent…
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License